Physician profile
Julius A Bishop
NPI 1548381999
$349,422.58
in general payments reported to CMS, 2019-2025
24 companies · $91K in 2025
The $91K reported for 2025 was more than what 95% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $35K · 2021: $27K · 2022: $33K · 2023: $61K · 2024: $30K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $129K · Travel and Lodging: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,012 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $128,850.00 |
| Travel and Lodging | $28,517.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,750.00 |
| Food and Beverage | $7,012.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $296,539.66 | 2019-2025 | Axsos, Gamma, Hoffmann |
| Synthes Gmbh | $23,811.23 | 2019-2025 | |
| Arthrex, INC. | $17,833.45 | 2025 | |
| Globus Medical, INC. | $3,859.08 | 2019-2025 | Durapro, Autobahn, Anthem |
| Heron Therapeutics, INC. | $2,392.95 | 2022 | |
| Depuy Synthes Sales INC. | $1,224.51 | 2019-2025 | Na, Tfn-Advance |
| Kci USA, INC. | $532.86 | 2019-2023 | |
| Osteocentric Technologies, INC. | $520.81 | 2019-2025 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Evolution Surgical, INC | $376.98 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $356.91 | 2019-2020 | |
| Si-Bone, INC. | $289.46 | 2020-2025 | |
| Solventum Corporation | $269.36 | 2024-2025 | Prevena |
| Flower Orthopedics Coporation | $161.57 | 2021 | |
| Paragon 28, INC. | $159.56 | 2024 | Phantom Fibula Nail |
| Orthofix Medical, INC. | $156.25 | 2024 | Truelok Evo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $151.43 | 2023-2025 | Avance Nerve Graft, Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector |
| Innovation Technologies INC | $149.16 | 2023 | Irrisept |
| Kerecis Limited | $145.16 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Acera Surgical, INC. | $112.21 | 2024-2025 | Restrata Wound Matrix |
| Curvafix, INC. | $111.00 | 2022 | |
| Smith+Nephew, INC. | $104.01 | 2024 | Synergy |
| Nuvasive Specialized Orthopedics, INC. | $95.64 | 2023 | Precice Intramedullary Limb Lengthening System |
| Davol INC. | $39.97 | 2025 | Arista |
| Ethicon US, LLC | $29.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.